# Nuclide record nct06520345 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06520345/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06520345", "NCT06520345" ;
  schema:name "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)"@en ;
  schema:description "A phase 3 trial of FAP-2286, Enzalutamide, Abiraterone acetate in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06520345/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06520345> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fap-2286/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/docetaxel/> ;
  nuclide:companies <https://nuclide.cc/companies/telix/> .